Par Gets Approval for Depression Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Par Pharmaceutical Co.’s wholly-owned subsidiary, Kali Laboratories, Inc., received final approval from the FDA for its aNDA for tranylcypromine sulfate tablets, 10 mg. Tranylcypromine is the generic version of GlaxoSmithKline’s Parnate and is used for the treatment of depression. Annual U.S. sales of Parnate exceed $6 million. Par will begin shipping the product immediately....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters